If you are trying to work out whether 10x Genomics is attractively priced or already reflecting a lot of optimism, the starting point is understanding how its current market value lines up with the ...

10x Genomics is bolstering its commitment to scaling single cell experiments through the acquisition of Scale Biosciences. 10x has agreed to pay $30 million in cash and stock upfront, plus an ...

Biotech company 10x Genomics (NASDAQ:TXG) in Q2 CY2025, with sales up 12.9% year on year to $172.9 million. On the other hand, next quarter’s revenue guidance of $142 million was less impressive, ...

Taich stated, "We anticipate revenue to be in the range of $154 million to $158 million, representing 5% growth compared to Q3 at the midpoint." He explained, "We do not anticipate a material change ...